The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 5, 2016, Pages 995-1007

  Zamolodchikov, D ^a   Renne T ^b,c   Strickland, S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Alzheimer's disease; Amyloid peptides; Factor XI; Factor XII; Thrombin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BLOOD CLOTTING FACTOR 12; FIBRIN; THROMBIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; COMPLEMENT COMPONENT C1S INHIBITOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; BLOOD FLOW VELOCITY; BRAIN CIRCULATION; C57BL MOUSE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; NERVE CELL; NORMAL HUMAN; THROMBOSIS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD COAGULATION; BLOOD FLOW VELOCITY; CEREBROVASCULAR CIRCULATION; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XII; FEMALE; FIBRIN; HEALTHY VOLUNTEERS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NEURONS; THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 84959283644     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13209     Document Type: Article

References (69)

1. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 2012; 107: 101-24.
2. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, Tanzi RE. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 2013; 80: 385-401.
3. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000; 21: 321-30.
4. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease - lessons from pathology. BMC Med 2014; 12: 206.
5. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 2011; 46: 225-32.
6. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 2012; 32: 599-608.
7. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM, Strickland S. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 2010; 66: 695-709.
8. Jarre A, Gowert NS, Donner L, Munzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cell Signal 2014; 26: 2040-50.
9. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 2012; 32: 425-36.
10. van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb AG, Blauw GJ, van der Flier WM, Scheltens P, Barkhof F, van Buchem MA, van der Grond J. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 2014; 270: 205-11.
11. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY. Alzheimer disease and risk of stroke: a population-based cohort study. Neurology 2013; 80: 705-11.
12. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H, Kivipelto M. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010; 75: 1408-14.
13. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-22.
14. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46: 154-9.
15. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60: 1707-12.
16. Ratner J, Rosenberg G, Kral VA, Engelsmann F. Anticoagulant therapy for senile dementia. J Am Geriatr Soc 1972; 20: 556-9.
17. Walsh AC, Walsh BH, Melaney C. Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. J Am Geriatr Soc 1978; 26: 467-70.
18. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 2004; 24: 4181-6.
19. Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. Neurobiol Dis 2010; 40: 340-7.
20. Shibayama Y, Joseph K, Nakazawa Y, Ghebreihiwet B, Peerschke EI, Kaplan AP. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol 1999; 90: 89-99.
21. Bergamaschini L, Donarini C, Foddi C, Gobbo G, Parnetti L, Agostoni A. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 2001; 22: 63-9.
22. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-18.
23. Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 1994; 654: 234-40.
24. Renné T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-303.
25. Zamolodchikov D, Chen ZL, Conti BA, Renne T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci USA 2015; 112: 4068-73.
26. Ashby EL, Love S, Kehoe PG. Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. Neurobiol Aging 2012; 33: 1345-55.
27. Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 2001; 122: 1971-83.
28. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30.
29. Kokjohn TA, van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castano EM, Roher AE. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 2011; 1812: 1508-14.
30. Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001; 276: 17036-43.
31. Schreiber S, Bueche CZ, Garz C, Kropf S, Angenstein F, Goldschmidt J, Neumann J, Heinze HJ, Goertler M, Reymann KG, Braun H. The pathologic cascade of cerebrovascular lesions in SHRSP: is erythrocyte accumulation an early phase? J Cereb Blood Flow Metab 2012; 32: 278-90.
32. Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006; 27: 1733-9.
33. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging 2011; 32(Suppl. 1): S10-19.
34. Pesini P, Perez-Grijalba V, Monleon I, Boada M, Tarraga L, Martinez-Lage P, San-Jose I, Sarasa M. Reliable measurements of the beta-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis 2012; 2012: 604141.
35. Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buee L, Dartigues JF, Touchon J, Lambert JC, Berr C. Plasma amyloid-beta levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis 2013; 33: 381-91.
36. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 2008; 29: 1-11.
37. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 2008; 105: 14052-7.
38. Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic Abeta in different aggregation states. Methods Mol Biol 2011; 670: 13-32.
39. Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, Muller-Esterl W, Emons G, Sancken U, Engel W, Burfeind P. Targeted deletion of murine coagulation factor XII gene - a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-8.
40. Gailani D, Lasky NM, Broze GJ Jr. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997; 8: 134-44.
41. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
42. Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamsa A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broome M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renne T. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
43. Tchaikovski SN, van Vlijmen BJ, Rosing J, Tans G. Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost 2007; 5: 2079-86.
44. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
45. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-14.
46. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-32.
47. Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res 2005; 27: 869-81.
48. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, ten Cate H, Hack CE. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-26.
49. Squitti R, Salustri C, Siotto M, Ventriglia M, Vernieri F, Lupoi D, Cassetta E, Rossini PM. Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2010; 2011: 231595.
50. Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, van Deventer SJ, Hack CE, ten Cate H. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998; 92: 3294-301.
51. Konings J, Cugno M, Suffritti C, Ten Cate H, Cicardi M, Govers-Riemslag JW. Ongoing contact activation in patients with hereditary angioedema. PLoS ONE 2013; 8: e74043.
52. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 1999; 25: 81-97.
53. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-8.
54. van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem 1990; 265: 9591-4.
55. Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. Front Aging Neurosci 2015; 7: 136.
56. Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, Chen LH, Ho PW, Cheng OY, Ho JW, Lam KS. Plasma amyloid-beta oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 2012; 423: 697-702.
57. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm 2012; 119: 843-50.
58. Wuillemin WA, Bleeker WK, Agterberg J, Rigter G, ten Cate H, Hack CE. Clearance of human factor XIa-inhibitor complexes in rats. Br J Haematol 1996; 93: 950-4.
59. Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Wille DR, Wu W, Yates JW, et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl 2008; 2: 467-77.
60. Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M, McEvoy M, Attia J, Schofield PW, Sachdev PS. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J Alzheimers Dis 2015; 43: 1355-73.
61. Redondo M, Caliezi C, Biasiutti FD, Lammle B, Wuillemin WA. Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. Atherosclerosis 2001; 157: 417-22.
62. Vogel G, Dempfle CE, Spannagl M, Leskopf W. The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. Thromb Res 1996; 81: 241-51.
63. Giannitsis E, Siemens HJ, Mitusch R, Tettenborn I, Wiegand U, Schmucker G, Sheikhzadeh A, Stierle U. Prothrombin fragments F1 + 2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68: 269-74.
64. Zamolodchikov D, Strickland S. Abeta delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 2012; 119: 3342-51.
65. Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging 2015; 36: 608-17.
66. Nishimura N, Schaffer CB. Big effects from tiny vessels: imaging the impact of microvascular clots and hemorrhages on the brain. Stroke 2013; 44: S90-2.
67. Nguyen J, Nishimura N, Fetcho RN, Iadecola C, Schaffer CB. Occlusion of cortical ascending venules causes blood flow decreases, reversals in flow direction, and vessel dilation in upstream capillaries. J Cereb Blood Flow Metab 2011; 31: 2243-54.
68. Chen B, Cheng Q, Yang K, Lyden PD. Thrombin mediates severe neurovascular injury during ischemia. Stroke 2010; 41: 2348-52.
69. Ponitz V, Brugger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW; RACS Study Group. Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost 2009; 7: 277-87.